Author | Number of patients described | Genotype | Phenotype | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Hepato-splenomegaly | Pyoderma gangrenosum | Cystic acne | Arthritis | Growth failure | Other symptoms | White cell count (10^9/L) | C-reactive protein (mg/L) | Serum zinc (umol/L) | Serum calprotectin (mg/L) | |||
Our case (B Gillies Whiteside et al. 2022) [3] | 1 | E250K | No | No | No | No | No | Seizures secondary to bilateral infarction, speech and cognitive delay | 12.1 | 71 | > 160 | > 15,000 |
G Del Borello et al. 2021 [4] | 1 | E250K | Yes | No | No | No | Yes | Dysmorphic features, developmental delay, lymphadenopathy | Unknown | 300 | Unknown | Unknown |
P Dai et al. 2019 [5] | 1 | E250K | Yes | Unknown | Unknown | Yes | Unknown | Proteinuria | 1.4 | > 1000 | 98 | 5000 |
M Mejbri et al. 2019 [6] | 1 | E250K | Yes | Unknown | Unknown | Yes | Unknown | Multifocal osteomyelitis | Unknown | Unknown | Unknown | Unknown |
S Hashmi et al. 2018 [7] | 2 | E250K | Yes | Unknown | Unknown | Yes | Unknown | Lymphadenopathy | 2.1 | 460 | 111 | Unknown |
E257K | Yes | Unknown | Unknown | Yes | Yes | Lymphadenopathy | 1.8 | 251 | 143 | Unknown | ||
H Klotgen et al. 2018 [8] | 1 | E250K | Yes | No | Yes | Yes | Unknown | Ulceration, sterile osteomyelitis | Unknown | 68 | 140 | 2050 |
E Belelli et al. 2017 [9] | 1 | E250K | Yes | Unknown | Unknown | Yes | No | Nil | 2.8 | 84 | 388,000 | 2.6 × 10^6 |
E Lindwall et al. 2015 [10] | 1 | E250K | Yes | Yes | Yes | Yes | Unknown | Osteomyelitis, epistaxis, renal failure | Unknown | 65 | Unknown | Unknown |
K Khatibi et al. 2015 [11] | 1 | E257K | No | No | No | No | No | Cerebral artery vasculopathy and subarachnoid haemorrhage | Unknown | Unknown | Unknown | Unknown |
D Holzinger et al. 2015 [12] | 14 | E250K | Yes | Yes | No | Yes | No | Dermatitis, liver failure | 3.8 | 146 | 77 | Unknown |
E250K | Splenomegaly | No | No | No | Yes | Nil | 3.2 | 140 | 118 | Unknown | ||
E250K | Yes | No | No | Yes | Yes | Chronic necrotic lesions, muscular atrophy | 3.8 | 223 | 147 | Unknown | ||
E250K | Yes | Yes | No | Yes | Yes | Dermatitis, liver failure, impaired motor development | 1.5 | 60 | 82 | Unknown | ||
E250K | Yes | No | No | Yes | Yes | Chronic necrotic lesions | 5 | 138 | 113 | Unknown | ||
E250K | Yes | No | No | No | Yes | Abscesses | 4.5 | 206 | 211 | Unknown | ||
E250K | Yes | No | No | Yes | Yes | IgA nephropathy | 1.3 | 140 | 200 | Unknown | ||
E250K | No | No | No | No | Unknown | Nil | 4 | 57 | 98 | Unknown | ||
E250K | No | No | Yes | Yes | Unknown | Abscesses | 2.8 | 24 | 58 | Unknown | ||
E250K | Splenomegaly | No | No | Yes | Yes | Erythema multiforme, osteitis | 1.7 | 160 | 52 | Unknown | ||
E250K | Splenomegaly | Yes | No | Yes | No | Ulceration, von Willibrand Factor deficiency | 0.08 | 72 | 110 | Unknown | ||
E250K | Yes | No | No | No | Yes | Dactylitis, eczema, impaired motor development | 1.9 | 60 | 144 | Unknown | ||
E250K | Yes | Yes | No | Yes | Yes | Glomerulonephritis | 1.6 | 82 | 130 | Unknown | ||
E257K | Yes | Yes | Yes | No | No | Recurrent ear infections and hearing loss | 1.07 | 46 | 64 | Unknown | ||
A Demidowich et al. 2012 [13] | 5 | A230T | Unknown | Yes | Yes | Yes | Unknown | Sterile abscesses | Unknown | Unknown | Unknown | Unknown |
E250Q | Unknown | Yes | No | Yes | Yes | Sterile abscesses, sterile osteomyelitis, recurrent otitis | Unknown | Unknown | Unknown | Unknown | ||
A230T | Unknown | Yes | Yes | Yes | Unknown | Sterile abscesses, recurrent otitis | Unknown | Unknown | Unknown | Unknown | ||
A230T | Unknown | Yes | No | Yes | Unknown | Nil | Unknown | Unknown | Unknown | Unknown | ||
E250K | Yes | Yes | No | Yes | Unknown | Lymphadenopathy | Unknown | Unknown | Unknown | Unknown | ||
H Lee et al. 2012 [14] | 2 | E257K | Yes | Unknown | Unknown | Unknown | Yes | Osteomyelitis, epistaxis | 1.8 | 250 | > 122 | Unknown |
E250K | Unknown | Yes | Yes | Yes | Unknown | Ulceration | Unknown | < 5 | Unknown | Unknown | ||
B Isidor et al. 2009 [15] | 1 | Unknown | Yes | Unknown | Unknown | Yes | Yes | Chronic necrotic lesions, recurrent epistaxis | 9.9 | 223 | 24 | 2310 |
T Sugiura et al. 2006 [16] | 1 | Unknown | Unknown | Yes | No | Yes | Yes | Impaired development | 2.4 | 60 | 182 | 12,500 |
S Fessatou et al. 2005 [17] | 1 | Unknown | Unknown | Unknown | Unknown | Unknown | Yes | Nil | 7 | 140 | 4.7 | 2923 |
B Sampson et al. 2002 [18] | 5 | Unknown | Yes | No | No | Yes | Yes | Vasculitis | 2 | 143 | 200 | 6500 |
Unknown | Yes | No | No | Yes | Yes | Nil | 5 | 200 | 96 | 2550 | ||
Unknown | Yes | No | No | Yes | Yes | Nil | 1.5 | 22 | 200 | 9000 | ||
Unknown | Yes | No | No | Yes | No | Vasculitis, uveitis, eczema | 5 | 17 | 175 | 6100 | ||
Unknown | Yes | No | No | Yes | No | Vasculitis, ulceration | 3.8 | 146 | 77 | 1500 |